Tiny study tracks cancer Drug's journey through the body

NCT ID NCT06713369

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study looks at how the experimental drug saruparib is absorbed, distributed, and eliminated in 8 people with advanced solid tumors. Participants will receive the drug by mouth and by vein, with samples taken to track the drug and its breakdown products. The goal is to understand the drug's behavior in the body, not to treat the cancer directly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Saruparib (AZD5305)
What this could lead to: If successful, this study will help determine the right dose of saruparib for future trials, potentially leading to better treatment options for advanced solid tumors.
What could go wrong: This is a very early, small study (only 8 people) focused on drug behavior, not on treating the cancer. It may not lead to any direct benefit for participants or future patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Liverpool, L7 8YA, United Kingdom
Research Site
RECRUITING

Manchester, M20 4BX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.